Page 97 - 2023 Taiwan Food and Drug Administration Annual Report

6Special Edition
so that medicinal products from Taiwan gain
prominence internationally. Representatives
from the medical, and pharmaceutical
industry and the government were invited
to attend the event; they explored strategies
to transform the domestic pharmaceutical
industries and to enhance competition from
the perspectives of clinical medication in
hospitals, suppliers of medicinal products,
and government administrators. They gave
keynote speeches on the topic of “Future
Development Opportunities and Blue Ocean
for the Pharmaceutical Industry in Taiwan”
and shared the research on the clinical use of countries and it is hoped that Taiwan will
domestic drugs, issues and challenges faced by become a crucial hub of the global biotech
the pharmaceutical industry, the development
trends and layout of the pharmaceutical
industry, and cases of how the industry has
successfully transformed on the basis of a
firm GMP foundation, to provide learning and
encouragement to the participants and give
valuable suggestions to the government.
▍ Achievements and Benefits
I. Pharmaceutical industry in
Taiwan are united to create a
new situation
The event was attended by more
than 300 people. Elites from the medical
community brainstormed and provided
advice on opportunities and challenges for
the pharmaceutical industry and how to boost
confidence in medicinal products produced
by domestic manufacturers. After the event,
TFDA also published a publication in memory
to witness the important moments throughout
the 40th anniversary of the implementation
of GMP in Taiwan and the 10th anniversary
of PIC/S membership. TFDA will continue
to work with the industry and improve the
professionalism of the industry in sync with
the international based on the firm GMP
foundation, so that the public can access to
medicine with the same quality as advanced
chain for the future.
II. Safeguarding global
medication together with
PIC/S
Since TFDA accessed the PIC/S in 2013,
we have used the PIC/S rapid alert to grasp
warnings on GMP violations of international
pharmaceutical manufacturers in real-time and
to activate dispositions for medicinal products
imported to Taiwan to implement consumer
protection. The PIC/S has been devoted to
the promotion of GMP Inspection Reliance in
recent years. TFDA also deepens collaborated
partnerships with other countries. The
accomplishments in the GMP management of
pharmaceutical manufacturers are obvious.
Results are accepted directly by other
95